• Arena Pharmaceuticals Reports Topline Results from Atopic Dermatitis Trial americanpharmaceuticalreview
    November 20, 2020
    Arena Pharmaceuticals announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of moderate-to-severe atopic dermatitis.
PharmaSources Customer Service